Skip to main content
. 2016 May 29;82(2):399–411. doi: 10.1111/bcp.12984

Figure 1.

Figure 1

Post hoc estimates of individual patient's lamotrigine clearance (CL) with the base population model according to co‐treatment with inhibitors of metabolism (A: Inline graphic None, Inline graphic Sertraline, Inline graphic Valproic acid), inducers (B: Inline graphic None, Inline graphic Carbamazepine, Inline graphic Phenobarbital, Inline graphic Phenytoin), cigarette smoking (C), ABCB1 2677G > C/A genotype (D), UGT2B7–161C > T genotype (E) and UGT2B7 372 A > G genotype (F)